Por: RTTNews Health October 06, 2022
Annovis Bio, Inc. (), a late-stage clinical drug platform company, announced Thursday that the U.S. Food and Drug Administration (FDA) has authorized the Phase 2/3 clinical study of buntanetap in moderate Alzheimer's Disease (AD).Following the submission of the Phase 2a clinical safety data and the chronic toxicology data in animals, the Company requested approval to further pursue the development of buntanetap in AD.The FDA approved the... + full article
CNN USA Health September 28, 2022
CNN — A monoclonal antibody treatment for Alzheimer’s disease called lecanemab slows the progression of cognitive decline by 27% compared with a placebo, drugmakers Biogen and Eisai said Tuesday. The drug, tested in a Phase 3 global clinical trial, also met all secondary... + más
New test can detect plaques early in the disease: Alzheimer's Q&A | The Advocate
Experimental Alzheimer’s drug slows cognitive decline in trial, firms say | Portland Press Herald
Newsweek USA Health September 24, 2022
The Alzheimer's Association defines Alzheimer's as a brain disease that causes a slow decline in memory, thinking and reasoning skills. Dementia refers to the symptoms of Alzheimer's that can worsen over time.They predict that by 2050, the number of people aged 65... + más
COVID-19 in seniors linked to increased Alzheimer’s risk, study finds | Portland Press Herald
There's a growing dementia crisis in the veteran community: Alzheimer's Q&A | The Advocate
Portland Press Herald USA Health September 24, 2022
A study using the electronic health records of more than 6 million Americans over age 65 found that those who had COVID-19 ran a greater risk of receiving a new diagnosis of Alzheimer’s disease within a year. The study, led by researchers at Case Western Reserve University... + más
How To Spot The Early Signs Of Alzheimer's | Newsweek
The Advocate USA Health September 17, 2022
Are U.S. veterans more at risk for Alzheimer’s or other dementias?The U.S. is in the midst of a dramatic rise in the number of veterans with Alzheimer’s disease and other dementias, and many of these new cases are directly attributable to military service.According to a 2017... + más
Stroke can lead to vascular dementia: Alzheimer's Q&A | The Advocate
Alzheimer's Q&A: Let go of negative thoughts | The Advocate
What is the Lumipulse test for Alzheimer’s disease?In May, the U.S. Food and Drug Administration permitted marketing of the Lumipulse (G B-Amyloid Ratio [1-42/1-40]) test to Fujirebio Diagnostics, Inc. of Malvern, Pennsylvania. The test, which was granted Breakthrough Device... + más
Variety of factors play a role in the development of Alzheimer's | The Advocate
Alzheimer's Q&A: Sildenafil has potential as Alzheimer's drug | The Advocate
How do you assess the risk of Alzheimer’s disease?Alzheimer’s disease is the only disease in the top 10 causes of death in the United States that cannot be prevented, slowed, or cured. It is not fully understood what causes the disease, but probable causes could be linked to... + más
Here's how to protect patients from scammers: Alzheimer's Q&A | The Advocate
What makes friends and family members often shy away from a loved one with Alzheimer’s disease or other dementias?There are many misconceptions about Alzheimer's that lead to fear of Alzheimer’s disease and other dementias. Negative public images and stereotypes... + más
About iurex | Privacy Policy | Disclaimer |